Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals. This is particularly noteworthy for BB Biotech since both Vertex (10.4%) and Crinetics (4.2%) were portfolio holdings as of 31 March 2026. More broadly, BB Biotech noted that the transaction provides further evidence of strategic value being created across the biotech sector, reinforcing the company’s conviction that innovation, clinical progress and commercial potential remain central to long term value creation.
Metals & Mining | Comment
Healthcare | Comment
Metals & Mining | Comment
Healthcare | Comment
Healthcare | Comment